ES2180754T3 - Compuestos y metodos para la deteccion de infeccion por t. cruzi. - Google Patents

Compuestos y metodos para la deteccion de infeccion por t. cruzi.

Info

Publication number
ES2180754T3
ES2180754T3 ES96910433T ES96910433T ES2180754T3 ES 2180754 T3 ES2180754 T3 ES 2180754T3 ES 96910433 T ES96910433 T ES 96910433T ES 96910433 T ES96910433 T ES 96910433T ES 2180754 T3 ES2180754 T3 ES 2180754T3
Authority
ES
Spain
Prior art keywords
cruzi
compounds
infection
detection
methods
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES96910433T
Other languages
English (en)
Inventor
Steven G Reed
Raymond L Houghton
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Corixa Corp
Original Assignee
Corixa Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Corixa Corp filed Critical Corixa Corp
Application granted granted Critical
Publication of ES2180754T3 publication Critical patent/ES2180754T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/44—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from protozoa
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56905—Protozoa
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/44—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from protozoa
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • General Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Food Science & Technology (AREA)
  • Virology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

SE DESCRIBEN LOS COMPUESTOS Y METODOS PARA EL DIAGNOSTICO DE LA INFECCION CON TRIPANOSOMA CRUZI O PARA LA DETECCION DE LA INFECCION CON T. CRUZI O LEISHMANIA. LOS COMPUESTOS DESCRITOS SON POLIPEPTIDOS O ANTICUERPOS PARA LOS MISMOS QUE CONTIENEN UNO O MAS EPITOPOS ANTIGENICOS DE LAS PROTEINAS DE T. CRUZI. LOS COMPUESTOS SON UTILES EN VARIOS INMUNOENSAYOS PARA LA DETECCION DE LA INFECCION CON T. CRUZI. LOS COMPUESTOS POLIPEPTIDICOS SON ADEMAS UTILES EN LAS VACUNAS Y EN LAS COMPOSICIONES FARMACEUTICAS PARA LA PREVENCION DE LA ENFERMEDAD DE CHAGAS EN INDIVIDUOS EXPUESTOS A T. CRUZI.
ES96910433T 1995-03-14 1996-03-12 Compuestos y metodos para la deteccion de infeccion por t. cruzi. Expired - Lifetime ES2180754T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/403,379 US5756662A (en) 1995-03-14 1995-03-14 Compounds and methods for the detection of T. cruzi infection

Publications (1)

Publication Number Publication Date
ES2180754T3 true ES2180754T3 (es) 2003-02-16

Family

ID=23595554

Family Applications (1)

Application Number Title Priority Date Filing Date
ES96910433T Expired - Lifetime ES2180754T3 (es) 1995-03-14 1996-03-12 Compuestos y metodos para la deteccion de infeccion por t. cruzi.

Country Status (13)

Country Link
US (2) US5756662A (es)
EP (1) EP0815450B1 (es)
JP (1) JPH11502923A (es)
AR (1) AR002282A1 (es)
AT (1) ATE220797T1 (es)
AU (1) AU5362696A (es)
BR (1) BR9607531A (es)
CA (1) CA2215104A1 (es)
DE (1) DE69622385T2 (es)
DK (1) DK0815450T3 (es)
ES (1) ES2180754T3 (es)
PT (1) PT815450E (es)
WO (1) WO1996029605A2 (es)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5756662A (en) * 1995-03-14 1998-05-26 Corixa Corporation Compounds and methods for the detection of T. cruzi infection
BR9503451A (pt) * 1995-07-26 1997-09-30 Mendes Rodolfo Pereira Processo de preparação de um antígeno derivado de um mocroorganismo causador de doença infecciosa e/ou parasitária processo de preparação de um antígeno de T cruzi antígeno derivado de midroorganismo causador de doença infecciosa e/ou parasitária antígeno derivado de T cruzi causador de doença de chagas composição a base de um antígeno derivado de microorganismo causador de doença infecciosa e/ou parasitária composição a base de antígeno de T cruzi utilização do antígeno derivado de microorganismo causador de doença infecciosa e/ou parasitária em testes sorológicos e vacinas utilização de antigeno derivado de T cruzi causador de doença de chagas em teste sorológico e vacinas processo para detecção de anticorpos anti antigeno de microorganismo causador de doença infecciosa e/ou parasitária e kit para sorodiagnóstico confirmatório para doença infecciosa e/ou parasitária
US5916572A (en) * 1995-11-14 1999-06-29 Corixa Corporation Compounds and methods for the detection and prevention of T. cruzi infection
US6228372B1 (en) 1997-04-15 2001-05-08 Corixa Corporation Compounds and methods for the detection and prevention of T. cruzi infection
US6054135A (en) * 1996-11-14 2000-04-25 Corixa Compounds and methods for the detection and prevention of T. cruzi infection
US6419933B1 (en) 1995-11-14 2002-07-16 Corixa Corporation Compounds and methods for the detection and prevention of T.cruzi infection
NZ337697A (en) 1997-03-11 2001-06-29 Stichting Dienst Landbouwkundi An ex vivo animal or challenge model as method to measure protective immunity directed against parasites and vaccines shown to be protective in said method
US6699722B2 (en) 2000-04-14 2004-03-02 A-Fem Medical Corporation Positive detection lateral-flow apparatus and method for small and large analytes
CA2498604A1 (en) * 2002-09-20 2004-04-01 Akzo Nobel N.V. Live antenuated parasite vaccine
CA2555989A1 (en) 2004-02-24 2005-09-01 Innogenetics N.V. Method for determining the risk of developing a neurological disease
US7888135B2 (en) * 2004-04-23 2011-02-15 University Of Georgia Research Foundation, Inc. Diagnostic assay for Trypanosoma cruzi infection
US8329411B2 (en) * 2004-04-23 2012-12-11 University Of Georgia Research Foundation, Inc. Diagnostic assay for Trypanosoma cruzi infection
EP1959996A2 (en) 2005-12-12 2008-08-27 AC Immune S.A. Monoclonal antibody
US7833534B2 (en) * 2006-04-10 2010-11-16 Infectious Disease Research Institute Compounds and methods for diagnosis and treatment of leishmaniasis
MY153248A (en) 2006-07-14 2015-01-29 Ac Immune Sa Humanized antibody against amyloid beta
EP2046833B9 (en) 2006-07-14 2014-02-19 AC Immune S.A. Humanized antibody against amyloid beta
US7749717B2 (en) * 2006-10-19 2010-07-06 Abbott Laboratories Methods for the detection and diagnosis of Trypanosoma cruzi infection
KR101450356B1 (ko) 2006-11-24 2014-10-15 에이씨 이뮨 에스.에이. 알츠하이머와 같은 아밀로이드 또는 아밀로이드-유사 단백질과 관련된 질환의 치료를 위한 ｎ-(메틸)-1ｈ-피라졸-3-아민, ｎ-(메틸)-피리딘-2-아민 및 ｎ-(메틸)-티아졸-2-아민 유도체
US8048420B2 (en) 2007-06-12 2011-11-01 Ac Immune S.A. Monoclonal antibody
NZ581835A (en) 2007-06-12 2012-09-28 Ac Immune Sa Monoclonal anti beta amyloid antibody
US8613923B2 (en) 2007-06-12 2013-12-24 Ac Immune S.A. Monoclonal antibody
ES2529174T3 (es) 2007-06-12 2015-02-17 Ac Immune S.A. Anticuerpos humanizados para amiloide beta
BRPI0818623A2 (pt) 2007-10-05 2017-05-23 Ac Immune Sa composição farmacêutica, e, métodos para reduzir a carga da placa na camada de célula de gânglio retinal de um animal, para reduzir a quantidade de placas na camada de célula de gânglio retinal de um animal, para diminuir a quantidade total de amilóide-beta solúvel na camada de célula de gânglio retinal de um animal, para prevenir, tratar e/ou aliviar os efeitos de uma doença ocular associada com anormalidades patológicas/mudanças no tecido do sistema visual, para monitorar doença ocular residual mínima associada com anormalidades patológicas/mudanças nos tecidos do sistema visual, para predizer responsividade de um paciente, e para reter ou diminuir a pressão ocular nos olhos de um animal
AU2008311367B2 (en) 2007-10-05 2014-11-13 Ac Immune S.A. Use of anti-amyloid beta antibody in ocular diseases
US20090203037A1 (en) 2007-12-27 2009-08-13 Abbott Laboratories Anti-T. Cruzi Antibodies and Methods of Use
WO2009158729A2 (en) * 2008-06-27 2009-12-30 The Infectious Disease Research Institute Inc. Compounds and methods for diagnosis and treatment of chagas disease
AR073452A1 (es) 2008-07-03 2010-11-10 Infectious Disease Res Inst Proteinas de fusion que comprende dos o mas antigenos de leishmania y su uso en el diagnostico y tratamiento de leishmaniasis
EP2311823A1 (en) 2009-10-15 2011-04-20 AC Immune S.A. 2,6-Diaminopyridine compounds for treating diseases associated with amyloid proteins or for treating ocular diseases
AU2011239966B2 (en) 2010-04-16 2014-05-08 Ac Immune S.A. Novel compounds for the treatment of diseases associated with amyloid or amyloid-like proteins
EP2377860A1 (en) 2010-04-16 2011-10-19 AC Immune S.A. Novel compounds for the treatment of diseases associated with amyloid or amyloid-like proteins
EP2598882B1 (en) 2010-07-30 2017-07-26 AC Immune S.A. Safe and functional humanized antibodies for use in treating an amyloidosis
MY164376A (en) 2010-10-07 2017-12-15 Univ Leuven Kath Phosphospecific antibodies recognizing tau
JP6027011B2 (ja) 2010-10-26 2016-11-16 エーシー イミューン ソシエテ アノニム 疎水性部分によって修飾されたペプチドを含むリポソームベースの構築物
KR101981351B1 (ko) 2011-10-07 2019-09-02 에이씨 이뮨 에스.에이. 타우를 인식하는 포스포특이적 항체
RU2644242C2 (ru) 2012-04-05 2018-02-08 Ац Иммуне С.А. Гуманизированное тау-антитело
EP2859017B1 (en) 2012-06-08 2019-02-20 Sutro Biopharma, Inc. Antibodies comprising site-specific non-natural amino acid residues, methods of their preparation and methods of their use
WO2014004639A1 (en) 2012-06-26 2014-01-03 Sutro Biopharma, Inc. Modified fc proteins comprising site-specific non-natural amino acid residues, conjugates of the same, methods of their preparation and methods of their use
EP2890402B1 (en) 2012-08-31 2019-04-17 Sutro Biopharma, Inc. Modified amino acids comprising an azido group
WO2014150877A2 (en) 2013-03-15 2014-09-25 Ac Immune S.A. Anti-tau antibodies and methods of use
WO2015006555A2 (en) 2013-07-10 2015-01-15 Sutro Biopharma, Inc. Antibodies comprising multiple site-specific non-natural amino acid residues, methods of their preparation and methods of their use
UA125204C2 (uk) 2013-09-05 2022-02-02 Аб2 Біо Са Застосування il-18-зв'язувального білка (il-18bp) при запальних захворюваннях
EP3055298B1 (en) 2013-10-11 2020-04-29 Sutro Biopharma, Inc. Modified amino acids comprising tetrazine functional groups, methods of preparation, and methods of their use
US10882905B2 (en) 2015-03-05 2021-01-05 Ab2 Bio Sa IL-18 binding protein (IL-18BP) and antibodies in inflammatory diseases
WO2017218698A1 (en) 2016-06-15 2017-12-21 Sutro Biopharma, Inc. Antibodies with engineered ch2 domains, compositions thereof and methods of using the same
GB201807367D0 (en) 2018-05-04 2018-06-20 Univ Newcastle Biomarker
US20230095053A1 (en) 2020-03-03 2023-03-30 Sutro Biopharma, Inc. Antibodies comprising site-specific glutamine tags, methods of their preparation and methods of their use
US20230173021A1 (en) 2020-05-06 2023-06-08 Ab2 Bio Sa IL-18 Binding Protein (IL-18BP) In Respiratory Diseases
EP3943097A1 (en) 2020-07-24 2022-01-26 AB2 Bio SA Car-t cell therapy
US20250179131A1 (en) 2022-03-04 2025-06-05 Ab2 Bio Sa Il-18 binding protein (il-18bp) in the treatment of vexas
EP4547701A1 (en) 2022-07-01 2025-05-07 Sutro Biopharma, Inc. Il-12 mutants with reduced toxicity, compositions thereof and methods of using the same
WO2024044780A1 (en) 2022-08-26 2024-02-29 Sutro Biopharma, Inc. Interleukin-18 variants and uses thereof
WO2024098023A2 (en) 2022-11-04 2024-05-10 Sutro Biopharma, Inc. Interferon alpha polypeptides and conjugates
WO2026043823A2 (en) 2024-08-19 2026-02-26 Sutro Biopharma, Inc. Antibodies comprising site-specific non-natural amino acid residues, methods of preparation and uses thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4870006A (en) * 1986-07-24 1989-09-26 Codon Antigenic material for a chagas' disease detection system
WO1990002564A1 (en) * 1988-09-12 1990-03-22 Codon Vaccine diagnostic employing proteins homologous to heat shock proteins of trypanosoma cruzi
BR9006039A (pt) * 1990-11-28 1992-07-14 Fundacao Oswaldo Cruz Processo para preparacao de antigeno conjugado a atividade enzimatica,composicao a base de conjugado enzima-antigeno para utilizacao em diagnostico imunologico e kits de diagnostico imunologico da doenca de chagas a base da dita composicao,para aplicacao individual e/ou em inqueritos epidemiologicos
US5304371A (en) * 1992-02-14 1994-04-19 Lasys Corporation Peptide for diagnosing and immunizing against T. cruzi infection
TW246717B (es) * 1992-07-10 1995-05-01 Abbott Lab
US5756662A (en) * 1995-03-14 1998-05-26 Corixa Corporation Compounds and methods for the detection of T. cruzi infection

Also Published As

Publication number Publication date
DE69622385T2 (de) 2003-03-06
EP0815450B1 (en) 2002-07-17
AU5362696A (en) 1996-10-08
DE69622385D1 (de) 2002-08-22
WO1996029605A3 (en) 1996-11-21
WO1996029605A2 (en) 1996-09-26
US5756662A (en) 1998-05-26
DK0815450T3 (da) 2002-10-28
EP0815450A2 (en) 1998-01-07
CA2215104A1 (en) 1996-09-26
ATE220797T1 (de) 2002-08-15
AR002282A1 (es) 1998-03-11
JPH11502923A (ja) 1999-03-09
MX9707020A (es) 1998-06-30
BR9607531A (pt) 1998-01-06
US5942403A (en) 1999-08-24
PT815450E (pt) 2002-12-31

Similar Documents

Publication Publication Date Title
ES2180754T3 (es) Compuestos y metodos para la deteccion de infeccion por t. cruzi.
ES2079638T3 (es) Anticuerpos humanizados.
BR0112602A (pt) Compostos e métodos para tratamento e diagnóstico de infecção clamidial
BR0016066A (pt) Compostos e métodos para tratamento e diagnóstico de infecção clamidial
ES2058049T1 (es) Composicion peptidica.
ES2075327T3 (es) Metodo para multiplicar linfocitos de sangre periferica humana in vitro que producen anticuerpos monoclonales especificos para un antigeno.
DK614987D0 (da) Syntetiske htlv-iii peptider, praeparater og anvendelser deraf
SE8704185D0 (sv) Nya peptider, artificiella antigener och immunoanalystestsatser
ES2130121T3 (es) Antigeno intra-acrosomico de esperma humano para uso en una vacuna anticonceptiva.
AR033832A1 (es) Un metodo ex vivo para diagnosticar una enfermedad autoinmune, anticuerpo, composicion de diagnostico que lo comprende, y usos del anticuerpo
ES2065863T1 (es) Ensayo del virus de la hepatitis c.
DK101888D0 (da) Immunmodulerende midler og anvendelse af disse
ES2118939T3 (es) Peptido para el diagnostico e inmunizacion contra la infeccion con t.cruzi.
ES2168520T3 (es) Compuestos y metodo para la deteccion y prevencion de infeccion por t. cruzi.
MX9301675A (es) Composiciones que contienen peptidos para inducir tolerancia de las celulas t a un antigeno.
DK0457804T3 (da) M-CSF-monoklonale antistoffer, som genkender en neutraliserende, konformational epitop
AR023634A1 (es) Una composicion que comprende al menos 6 peptidos recombinantes y/o sinteticos, un metodo para detectar la presencia de un anticuerpo de t.cruzi, en una muestra biologica, y un estuche de diagnostico para su deteccion
DE68921360D1 (de) Monoklonale Antikörper von Mäusen gegen das gp41 Protein von menschlichem Immunmangelsyndrom-Virus.
ATE375514T1 (de) Zusammensetzungen und methoden zur detektion einer trypanosoma cruzi infektion
CY1106349T1 (el) Συστηματα ανιχνευσης ανοσοπροσδιορισμου ιικου αντιγονου ηπατιτιδας c
DE69525058D1 (de) Präsentation von aus lipoarabinomannan bestehenden antigenen an t-zellen durch cd1 moleküle
FI910324A7 (fi) Menetelmät ja testipakkaukset ihmisen leukosyyttiantigeeni-DNA:n havaitsemiseksi
CO4820439A1 (es) Compuestos y metodos para la deteccion y la prevencion de la infeccion por el t. cruzi
McArthur et al. A rapid micro-method for screening eel sera for antibodies against the digenean Telogaster opisthorchis Macfarlane, 1945.
ES2113860T3 (es) Peptidos con grupos tioles de cisteina protegidos, utiles en los ensayos inmunologicos.